Japan’s Astellas Pharma Inc is buying U.S. drugmaker Audentes Therapeutics Inc for about $3 billion in cash, in a high-priced push to make genetic medicines a key area of growth. Gene therapies are one of the hottest...
Japan’s Astellas to buy Audentes for $3 billion in gene therapy push
Japan’s Astellas Pharma Inc has agreed to buy Audentes Therapeutics Inc for about $3 billion in cash as it seeks to make genetic medicines a key area of growth. Gene therapies are one of the hottest areas of drug...
Cipla gains as arm to buy 40% stake in Cipla Pharma Lanka
Shares of Cipla on Thursday rose nearly 2 per cent after the pharma major said its arm has signed an agreement with CitiHealth Imports to acquire remaining 40 per cent stake in Cipla Pharma Lanka. The pharma company on...
Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion – WSJ
Swiss drugmaker Novartis AG is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co for about $7 billion, the Wall Street Journal reported on Saturday. The deal, in which Novartis has agreed to pay...
Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug
Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene’s psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol...
NCLAT sets aside Dhanuka’s resolution plan for debt-laden Orchid Pharma
The National Company Law Appellate Tribunal (NCLAT) has set aside the approval of the resolution plan of Dhanuka Laboratories for Orchid Pharma. Dhanuka’s plan was approved by the NCLT on June 25. The Bench also...
Lupin to divest entire stake in Kyowa for Rs 3,702 crore
Drug major Lupin on Monday said its board has approved selling its entire stake in Japanese subsidiary Kyowa Pharmaceutical Industry to Japan-based private equity fund Unison Capital Partners for an enterprise value of...
Novartis buys Aspen’s Japanese generic unit for up to 400 million euros
Novartis is buying the Japanese generics unit of South Africa’s Aspen Pharmacare in a deal worth up to 400 million euros ($440.80 million) to expand in the world’s third-biggest drug market, the Swiss drugmaker said on...
Aurobindo’s buyout of Sandoz assets delayed on FTC query
Aurobindo Pharma’s acquisition of the dermatology and generics business of Novartis’ Sandoz subsidiary is delayed further, as the US Federal Trade Commission (FTC) has asked for more information on a lawsuit the Indian...
Stada buys Takeda drug bundle to boost Russia business
Germany’s Stada on Tuesday agreed to purchase over-the-counter and prescription drugs units from Japan’s largest drugmaker Takeda for $660 million, part of two deals that boost its Russian and Eastern European footprint...
Walgreens has explored taking drug store chain private – sources
Walgreens Boots Alliance Inc has been exploring whether to go private following private equity interest in the U.S drug store chain, which has a market value of more than $55 billion, according to people familiar with...
Lupin looks to sell Japanese arm Kyowa for $600 million
India’s Lupin Ltd is in advanced talks to sell its Japanese generics subsidiary Kyowa Pharmaceuticals for an enterprise value of $600 million to a local player as it steps up efforts to significantly cut operations in...
